JW Pharmaceutical Receivables

The latest receivables for 001067.KS is $120B as of June 2026. That compares with $130B in the prior-year period — down 6.0% year over year. Investors often review this figure alongside JW Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 001067.KS's receivables moved from $130B to $120B — a 6.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in JW Pharmaceutical's operating scale or balance-sheet position.

A receivables figure of $120B for 001067.KS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 001067.KS's receivables ($120B), review year-over-year change from $130B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.